RxDoctor Payments Data

Nelson Ferreira, MD

Gastroenterology · Hagerstown, MDNPI 1679563746

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,800 of the $12,769 with a category attached, or 84.6%. Phathom Pharmaceuticals, Inc. accounts for 98.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $10,088 and has fallen 75.7% since, to $2,452 in 2025.

$12,769in general payments, 2019–2025

Across 22 payments — averaging $580.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$13K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$171
  • AbbVie$76
$219,697in research payments, 2019–2025

Across 62 payments — averaging $3543.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$137K
  • Ironwood Pharmaceuticals, Inc$36K
  • AbbVie$27K
  • Regeneron$15K
  • Braintree Laboratories, Inc.$4K

What the payments were for

  • Speaking & faculty fees$10,80085%
  • Travel & lodging$1,1409%
  • Food & beverage$8286%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,769 in reported general payments places this provider in the 85th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$56,716
Medicare patients
440
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide20$23,864
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates61$3,667
Famotidine150$3,536
Colesevelam Hcl39$3,027
ClenpiqSod Picosulf/Mag Ox/Citric Ac17$2,874
Esomeprazole Magnesium25$1,911
Omeprazole130$1,902
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl120$1,867
Colestipol Hcl33$1,495
Pantoprazole Sodium109$1,314
Dicyclomine Hcl40$974
Ondansetron OdtOndansetron13$207
Sucralfate12$178
Ondansetron Hcl20$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$76$23,86420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →